Difference between revisions of "RHEUMATOID ARTHRITIS-INTRODUCTION"
(Imported from text file) |
(Imported from text file) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 4: | Line 4: | ||
<br/>2. Primarily affects the synovial lining of diarthrodial joints (joints composed of type II hyaline cartilage, subchondral bone, synovial membrane, synovial fluid, joint capsule). | <br/>2. Primarily affects the synovial lining of diarthrodial joints (joints composed of type II hyaline cartilage, subchondral bone, synovial membrane, synovial fluid, joint capsule). | ||
<br/> | <br/> | ||
<br/>3. Rheumatoid factor | <br/>3. Rheumatoid factor: heterogenous antibodies directed against the F<sub>c</sub> portion of IgG antibodies. | ||
<br/> | <br/> | ||
<br/>4. F:M ratio is 2:1, peak age of onset 55 years. | <br/>4. F:M ratio is 2:1, peak age of onset 55 years. | ||
| Line 12: | Line 12: | ||
==Reference(s)== | ==Reference(s)== | ||
Wilkinson, I. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. | Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. [https://amzn.to/3YHrI6K Get it on Amazon.] | ||
<br/>Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. [https://amzn.to/3k7WSW0 Get it on Amazon.] | |||
<br/>Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy. | <br/>Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy. | ||
<br/>Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021]. | <br/>Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021]. | ||
Latest revision as of 11:07, 20 March 2023
SUMMARY
1. Systemic, autoimmune, inflammatory, symmetric, peripheral polyarthritis of unknown etiology.
2. Primarily affects the synovial lining of diarthrodial joints (joints composed of type II hyaline cartilage, subchondral bone, synovial membrane, synovial fluid, joint capsule).
3. Rheumatoid factor: heterogenous antibodies directed against the Fc portion of IgG antibodies.
4. F:M ratio is 2:1, peak age of onset 55 years.
5. Increased risk of CV diseases, lung diseases, depression, OP, malignancies (lymphoma, lung, skin CA).
Reference(s)
Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].
